Search

George Carlone Phones & Addresses

  • Palm Coast, FL
  • 5243 Sandy Shoals Ln, Stone Mtn, GA 30087 (770) 498-4374 (770) 879-0799
  • Stone Mountain, GA
  • Snellville, GA
  • San Diego, CA
  • 10 Lakeside Pl E, Palm Coast, FL 32137 (770) 498-4374

Work

Position: Protective Service Occupations

Education

Degree: Associate degree or higher

Business Records

Name / Title
Company / Classification
Phones & Addresses
George M. Carlone
Managing
Carlone Consulting LLC
Business Consulting Services
10 Lakeside Pl E, Palm Coast, FL 32137

Publications

Us Patents

Streptococcus Pneumoniale 37-Kda Surface Adhesion A Protein

View page
US Patent:
6773880, Aug 10, 2004
Filed:
Jan 3, 2001
Appl. No.:
09/754809
Inventors:
Jacquelyn Sampson - College Park GA
Harold Russell - Efland NC
Jean A. Tharpe - Lithonia GA
Edwin W. Ades - Atlanta GA
George M. Carlone - Stone Mountain GA
Assignee:
The United States of America as represented by the Department of Health and Human Services - Washington DC
International Classification:
C12Q 168
US Classification:
435 6, 536 237, 536 2432, 536 2433
Abstract:
The invention provides a nucleic acid encoding the 37-kDa protein from. Also provided are isolated nucleic acids comprising a unique fragment of at least 10 nucleotides of the 37-kDa protein. The invention also provides purified polypeptides encoded by the nucleic acid encoding the 37-kDa protein from and the nucleic acids comprising a unique fragment of at least 10 nucleotides of the 37-kDa protein. Also provided are antibodies which selectively binds the polypeptides encoded by the nucleic acid encoding the 37-kDa protein and the nucleic acids comprising a unique fragment of at least 10 nucleotides of the 37-kDa protein. Also provided are vaccines comprising immunogenic polypeptides encoded by the nucleic acid encoding the 37-kDa protein and the nucleic acids comprising a unique fragment of at least 10 nucleotides of the 37-kDa protein. Further provided is a method of detecting the presence of in a sample comprising the steps of contacting a sample suspected of containing with nucleic acid primers capable of hybridizing to a nucleic acid comprising a portion of the nucleic acid encoding the 37-kDa protein, amplifying the nucleic acid and detecting the presence of an amplification product, the presence of the amplification product indicating the presence of in the sample. Further provided are methods of detecting the presence of in a sample using antibodies or antigens, methods of preventing and treating infection in a subject.

Peptide Vaccines Against Group A Streptococci

View page
US Patent:
8420107, Apr 16, 2013
Filed:
Mar 22, 2012
Appl. No.:
13/427477
Inventors:
Bernard W. Beall - Doraville GA,
George M. Carlone - Stone Mountain GA,
Jacquelyn S. Sampson - College Park GA,
Edwin W. Ades - Atlanta GA,
Assignee:
The United States of America, as represented by the Secretary, Department of Health and Human Services, Centers for Disease Control and Prevention - Washington DC
International Classification:
A61K 39/09
C07K 14/315
US Classification:
4242441, 4241841, 4242341, 530300, 530350
Abstract:
This invention, in one aspect, relates to synthetic immunoreactive peptides. These peptides are approximately 20-25 amino acids in length which are portions of the N termini of the M proteins of the most prevalent United States (U. S. ) Group A (GAS) serotypes. At least some of the synthetic peptides can be recognized by M type-specific antibodies and are capable of eliciting functional opsonic antibodies and/or anti-attachment antibodies without eliciting tissue cross-reactive antibodies. In another aspect, it relates to compositions or vaccines comprising these synthetic serotype-specific peptides, including polypeptides and proteins. The invention may also be isolated antibodies which are raised in response to the peptides, compositions or vaccines. The invention further relates to kits for using the peptides, compositions, or antibodies. In still further aspects, the invention also relates to methods for using the peptides, compositions, vaccines, or antibodies and methods for tailoring vaccines.

Immunodiagnostic Reagent Specific For Legionella

View page
US Patent:
52485943, Sep 28, 1993
Filed:
Jul 5, 1990
Appl. No.:
7/548011
Inventors:
Carol H. Aloisio - Norcross GA
George M. Carlone - Stone Mountain GA
Bonnie B. Plikaytis - Tucker GA
Jackie Sampson - College Park GA
Assignee:
The United States of America as represented by the Department of Health
and Human Services - Washington DC
International Classification:
G01N 33569
C07K 1528
US Classification:
435 732
Abstract:
A set of three unique monoclonal antibodies have been produced which recognize Legionella with particular specificity, without substantial cross-reactivity with non-Legionella bacteria. These monoclonal antibodies are useful as immunodiagnostic reagents for detecting Legionella.

Streptococcus Pneumoniae 37-Kda Surface Adhesin A Protein And Nucleic Acids Coding Therefor

View page
US Patent:
58544160, Dec 29, 1998
Filed:
Sep 17, 1996
Appl. No.:
8/715131
Inventors:
Jacquelyn S. Sampson - College Park GA
Harold Russell - Atlanta GA
Jean A. Tharpe - Lithonia GA
Edwin W. Ades - Atlanta GA
George M. Carlone - Stone Mountain GA
Assignee:
The United States of America as represented by the Department of Health
and Human Services - Washington DC
International Classification:
C07H 2104
US Classification:
536 237
Abstract:
The invention provides a nucleic acid encoding the 37-kDa protein from Streptococcus pneumoniae. Also provided are isolated nucleic acids comprising a unique fragment of at least 10 nucleotides of the 37-kDa protein. The invention also provides purified polypeptides encoded by the nucleic acid encoding the 37-kDa protein from and the nucleic acids comprising a unique fragment of at least 10 nucleotides of the 37-kDa protein. Also provided are antibodies which selectively binds the polypeptides encoded by the nucleic acid encoding the 37-kDa protein and the nucleic acids comprising a unique fragment of at least 10 nucleotides of the 37-kDa protein. Also provided are vaccines comprising immunogenic polypeptides encoded by the nucleic acid encoding the 37-kDa protein and the nucleic acids comprising a unique fragment of at least 10 nucleotides of the 37-kDa protein. Further provided is a method of detecting the presence of Streptococcus pneumoniae in a sample comprising the steps of contacting a sample suspected of containing Streptococcus pneumoniae with nucleic acid primers capable of hybridizing to a nucleic acid comprising a portion of the nucleic acid encoding the 37-kDa protein, amplifying the nucleic acid and detecting the presence of an amplification product, the presence of the amplification product indicating the presence of Streptococcus pneumoniae in the sample. Further provided are methods of detecting the presence of Streptococcus pneumoniae in a sample using antibodies or antigens, methods of preventing and treating Streptococcus pneumoniae infection in a subject.

Streptococcus Pneumoniae 37-Kda Surface Adhesin A Protein

View page
US Patent:
62178849, Apr 17, 2001
Filed:
Dec 28, 1998
Appl. No.:
9/221753
Inventors:
Jacquelyn S. Sampson - College Park GA
Harold Russell - Atlanta GA
Jean A. Tharpe - Lithonia GA
Edwin W. Ades - Atlanta GA
George M. Carlone - Stone Mountain GA
Assignee:
The United States of America as represented by the Department of Health and
Human Services - Washington DC
International Classification:
A61K 3909
US Classification:
4242441
Abstract:
The invention provides a nucleic acid encoding the 37-kDa protein from Streptococcus pneumoniae. Also provided are isolated nucleic acids comprising a unique fragment of at least 10 nucleotides of the 37-kDa protein. The invention also provides purified polypeptides encoded by the nucleic acid encoding the 37-kDa protein from and the nucleic acids comprising a unique fragment of at least 10 nucleotides of the 37-kDa protein. Also provided are antibodies which selectively binds the polypeptides encoded by the nucleic acid encoding the 37-kDa protein and the nucleic acids comprising a unique fragment of at least 10 nucleotides of the 37-kDa protein. Also provided are vaccines comprising immunogenic polypeptides encoded by the nucleic acid encoding the 37-kDa protein and the nucleic acids comprising a unique fragment of at least 10 nucleotides of the 37-kDa protein. Further provided is a method of detecting the presence of Streptococcus pneumoniae in a sample comprising the steps of contacting a sample suspected of containing Streptococcus pneumoniae with nucleic acid primers capable of hybridizing to a nucleic acid comprising a portion of the nucleic acid encoding the 37-kDa protein, amplifying the nucleic acid and detecting the presence of an amplification product, the presence of the amplification product indicating the presence of Streptococcus pneumoniae in the sample. Further provided are methods of detecting the presence of Streptococcus pneumoniae in a sample using antibodies or antigens, methods of preventing and treating Streptococcus pneumoniae infection in a subject.

Use Of A Pneumococcal P4 Peptide For Enhancing Opsonophagocytosis In Response To A Pathogen

View page
US Patent:
20130195893, Aug 1, 2013
Filed:
Mar 27, 2013
Appl. No.:
13/851508
Inventors:
The Government of the United States of America as represented by the Secretary of the Department of He - Atlanta GA,
Gowrisankar Rajam - Tucker GA,
Sandra Steiner - Atlanta GA,
George M. Carlone - Stone Mountain GA,
Nikkol Melnick - Braselton GA,
Jacquelyn S. Sampson - College Park GA,
Joseph E. Martinez - McDonough GA,
Julie M. Skinner - Schwenksville PA,
Assignee:
The Government of the United States of America as represented by the Secretary of the department of - Atlanta GA
International Classification:
A61K 38/16
A61K 45/06
A61K 39/42
A61K 39/395
A61K 39/40
US Classification:
4241591, 4241301, 514 23, 4241641, 4241651
Abstract:
Methods for enhancing opsonophagocytosis of a pathogen of interest are disclosed. The disclosed methods include administering to a subject an isolated P4 peptide, which includes the amino acid sequence set forth as SEQ ID NO: 1 and optionally an isolated opsonic antibody or a fragment thereof that specifically binds to an antigen present on the surface of the pathogen of interest. In some examples isolated complement protein or a fragment thereof (for example, a C3a, C3b, iC3b, C3d, C4b, or C5a fragment of a complement protein) is also administered. Compositions containing isolated P4 peptide and one or more isolated opsonic antibodies or a fragment thereof that specifically binds to an antigen present on the surface of a pathogen of interest are also disclosed. In some examples, the compositions also include isolated complement protein or fragment thereof, such as one or more of C3a, C3b, iC3b, C3d, C4b, or C5a.

Peptide Vaccines Against Group A Streptococci

View page
US Patent:
20110110969, May 12, 2011
Filed:
Dec 20, 2010
Appl. No.:
12/973247
Inventors:
Bernard W. Beall - Doraville GA,
George M. Carlone - Stone Mountain GA,
Jacquelyn S. Sampson - College Park GA,
Edwin W. Ades - Atlanta GA,
International Classification:
A61K 39/09
C07K 14/315
A61P 31/04
A61K 39/116
US Classification:
4241901, 530326, 530325, 530324
Abstract:
This invention, in one aspect, relates to synthetic immunoreactive peptides. These peptides are approximately 20-25 amino acids in length which are portions of the N termini of the M proteins of the most prevalent United States (U.S.) Group A (GAS) serotypes. At least some of the synthetic peptides can be recognized by M type-specific antibodies and are capable of eliciting functional opsonic antibodies and/or anti-attachment antibodies without eliciting tissue cross-reactive antibodies. In another aspect, it relates to compositions or vaccines comprising these synthetic serotype-specific peptides, including polypeptides and proteins. The invention may also be isolated antibodies which are raised in response to the peptides, compositions or vaccines. The invention further relates to kits for using the peptides, compositions, or antibodies. In still further aspects, the invention also relates to methods for using the peptides, compositions, vaccines, or antibodies and methods for tailoring vaccines.

Multiple-Valent Opsonophagocytic Assay Selection Panel Arrays And Uses Therefor

View page
US Patent:
20100099138, Apr 22, 2010
Filed:
Nov 18, 2009
Appl. No.:
12/620772
Inventors:
Sandra STEINER - Atlanta GA,
Patricia F. HOLDER - Mableton GA,
George M. CARLONE - Stone Mountain GA,
GowriSankar RAJAM - Tucker GA,
International Classification:
C12Q 1/18
US Classification:
435 32
Abstract:
This application discloses a multivalent opsonophagocytosis assay that does not rely on counting of bacterial colonies to determine bacteria viability following opsonophagocytosis. Instead, the method uses a metabolic colorimetric indicator to determine if viable bacteria are present. Also disclosed are arrays that can be used to determine the viability of bacteria following opsonophagocytosis.
George M Carlone from Palm Coast, FL, age ~73 Get Report